Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine Inc (HYPR) pioneers accessible MRI technology through its groundbreaking Swoop® Portable MR Imaging System, transforming diagnostic capabilities in critical care and underserved settings. This page serves as the definitive source for verified news and announcements related to corporate developments, clinical milestones, and financial performance.
Investors and healthcare professionals will find timely updates on regulatory clearances, partnership agreements, quarterly earnings, and technological advancements. Our curated collection includes press releases about device deployments, peer-reviewed study results, and strategic initiatives driving portable MRI adoption.
Key coverage areas include Swoop system innovations, financial results analysis, leadership updates, and market expansion efforts. All content is rigorously verified to ensure accuracy and relevance for stakeholders evaluating HYPR's position in the medical imaging sector.
Bookmark this page for streamlined access to Hyperfine's latest progress in redefining bedside diagnostics through ultra-low-field MRI technology. Check regularly for objective reporting on developments impacting both clinical practice and long-term corporate strategy.
Hyperfine, Inc. (NASDAQ: HYPR), pioneer of the Swoop® system, the first FDA-cleared portable MRI system, announced it will report its Q1 2023 financial results on May 11, 2023. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Swoop® provides neuroimaging at the point of care, offering bedside imaging capabilities where traditional MRI access is limited or unavailable. Initially cleared by the FDA in 2020, it is now also approved in Canada, Australia, and other regions, enhancing patient care through accessible diagnostic imaging. Interested investors can access the live audio webcast via the company’s website.
Hyperfine, Inc. (Nasdaq: HYPR) reported fourth quarter and full year 2022 financial results, achieving revenue of $6.8 million for the year, up from $1.5 million in 2021. In Q4 2022, revenue was $1.424 million, compared to $0.436 million in Q4 2021. The net loss for the year was $73.164 million, or $1.04 per share, an increase from $64.851 million or $17.57 per share in the previous year. The company ended the year with $117.472 million in cash. 2023 guidance estimates revenue between $10 to $14 million with a cash burn of $40 to $45 million. Significant achievements included FDA clearances and the installation of 35 commercial systems.
FAQ
What is the current stock price of HYPERFINE (HYPR)?
What is the market cap of HYPERFINE (HYPR)?
